Glomerulonephritis management is a specialized field of nephrology dedicated to diagnosing and treating immune-mediated inflammatory diseases of the renal glomeruli. The treatment combines targeted immunomodulatory agents to arrest autoantibody production or immune complex deposition with blood pressure and protein-sparing therapies to protect remaining kidney tissue. Grounded in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, management strategies are tailored to specific histopathological disease subtypes.

Glomerulonephritis management starts with diagnostic verification using blood tests, 24-hour urine collection, and percutaneous renal biopsy under ultrasound guidance. Pharmacological therapy begins with induction protocols using systemic corticosteroids combined with immunosuppressants like cyclophosphamide, rituximab, or mycophenolate mofetil. Parallel supportive therapy includes renin-angiotensin-aldosterone system inhibitors, such as ACE inhibitors or angiotensin receptor blockers, alongside SGLT2 inhibitors to reduce intraglomerular pressure. Patients undergo serial monitoring of blood counts, kidney markers, and immunologic titers every 2 to 4 weeks during induction, transitioning to every 3 to 6 months during maintenance.

Evidence-based management of glomerulonephritis achieves disease remission, reduces urinary protein loss, preserves the estimated glomerular filtration rate (a measure of overall renal function), and significantly decreases the long-term risk of progression to end-stage kidney disease requiring renal replacement therapy. Furthermore, protocolized immunosuppression regimens minimize adverse drug effects while preventing severe systemic complications such as cardiovascular disease, malignant hypertension, and fluid overload.

Recovery timing in glomerulonephritis management varies by clinical subtype and severity of initial tissue damage. Laboratory markers such as urine protein-to-creatinine ratio and serum creatinine typically begin improving within two to twelve weeks after starting induction therapy. Complete clinical remission or stabilization often requires six to twenty-four months of ongoing maintenance treatment, during which medication dosages are gradually reduced while maintaining strict renal and cardiovascular monitoring.

Glomerulonephritis management addresses primary and secondary glomerular disorders, including IgA nephropathy (an immune complex kidney disease), membranous nephropathy (an autoimmune disorder affecting the glomerular basement membrane), lupus nephritis (kidney inflammation from systemic lupus erythematosus), ANCA-associated vasculitis (small vessel autoimmune inflammation), focal segmental glomerulosclerosis (scarring of renal filtering units), and anti-glomerular basement membrane disease.

Preparation for glomerulonephritis treatment involves comprehensive clinical baseline testing, including renal ultrasound, metabolic panels, complete blood count, and baseline quantitative proteinuria measurement. Patient preparation for renal biopsy requires stopping antiplatelet and anticoagulant medications under medical supervision, screening for bleeding disorders, and controlling blood pressure below 140/90 mmHg. Screening for latent infection, such as hepatitis B, hepatitis C, tuberculosis, and varicella zoster, is essential prior to initiating high-dose immunosuppressive therapy.

Risks of glomerulonephritis management are primarily related to immunosuppression and renal biopsy procedures. Biopsy complications include localized hematoma (1-5%), gross hematuria (2-4%), and severe hemorrhage requiring intervention (<0.5%). Immunosuppressive side effects include severe opportunistic infections, leukopenia (low white cell count), steroid-induced diabetes, hypertension, osteoporosis, elevated liver enzymes, and secondary malignancy. Targeted monitoring protocols mitigate these risks through antimicrobial prophylaxis and routine laboratory surveillance.

The clinical journey in glomerulonephritis management begins with detailed diagnostic evaluation, including laboratory serum tests, urinalysis, and a percutaneous kidney biopsy. Once a histopathological diagnosis is established, patients enter an induction phase using potent immunosuppressive medications to arrest active inflammation. This is followed by a long-term maintenance phase focusing on disease remission, blood pressure control, and serial monitoring of renal function, culminating in routine clinical follow-up to detect and manage potential disease relapses.